The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Exosome‐delivered circRNA promotes glycolysis to induce chemoresistance through the miR‐122‐PKM2 axis in colorectal cancer
Open accessAbstract
Malignant tumors, including colorectal cancer (CRC), usually rely on ATP generation through aerobic glycolysis for both rapid growth and chemotherapy resistance. The M2 isoform of pyruvate kinase (PKM2) has a key role in catalyzing glycolysis, and PKM2 expression varies even within a single tumor. In this study, we confirmed that expression of PKM2 is heterogeneous in CRC cells, namely high in oxaliplatin‐resistant cells but relatively low in sensitive cells, and found that chemoresistant cells had enhanced glycolysis and ATP production. In addition, we report a PKM2‐dependent mechanism through which chemosensitive cells may gradually transform into chemoresistant cells. The circular RNA hsa_circ_0005963 (termed ciRS‐122 in this study), which was determined to be a sponge for the PKM2‐targeting miR‐122, was positively correlated with chemoresistance. In vitro and in vivo studies showed that exosomes from oxaliplatin‐resistant cells delivered ciRS‐122 to sensitive cells, thereby promoting glycolysis and drug resistance through miR‐122 sponging and PKM2 upregulation. Moreover, si‐ciRS‐122 transported by exosomes could suppress glycolysis and reverse resistance to oxaliplatin by regulating the ciRS‐122–miR‐122–PKM2 pathway in vivo . Exosomes derived from chemoresistant CRC cells could transfer ciRS‐122 across cells and promote glycolysis to reduce drug susceptibility in chemosensitive cells. This intercellular signal delivery suggests a potential novel therapeutic target and establishes a foundation for future clinical applications in drug‐resistant CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Zhang, H., Deng, T., Ge, S., Liu, Y., Bai, M., Zhu, K., Fan, Q., Li, J., Ning, T., Tian, F., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0619-z · Cited by 303
Self-citationRetractedZhang, H., Zhu, L., Bai, M., Liu, Y., Zhan, Y., Deng, T., Yang, H., Sun, W., Wang, X., Zhu, K., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.31977 · Cited by 210
Self-citationRetractedThéry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099
The Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150 · cited 2×
“Malignant solid tumors take up large amounts of glucose to produce lactate even in the presence of oxygen compared with what is observed in the surrounding tissue; this phenomenon has been termed ‘aerobic glycolysis’ (Liberti and Locasale, 2016).”
BackgroundMathieu, M., Martin-Jaular, L., Lavieu, G., & Théry, C. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0250-9 · Cited by 3,737
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866 · cited 2×
“Nevertheless, the development of the ABC transporter as a therapeutic target has been unsuccessful in 30 years of research (Robey et al., 2018).”
BackgroundThe Landscape of Circular RNA in Cancer
Vo, J. N., Cieslik, M., Zhang, Y., Shukla, S., Xiao, L., Zhang, Y., Wu, Y.-M., Dhanasekaran, S. M., Engelke, C. G., Cao, X., et al. (2019) · Cell · doi:10.1016/j.cell.2018.12.021 · Cited by 1,738
Extracellular vesicles in cancer — implications for future improvements in cancer care
Xu, R., Rai, A., Chen, M., Suwakulsiri, W., Greening, D. W., & Simpson, R. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0036-9 · Cited by 1,445
Circular RNAs in cancer: opportunities and challenges in the field
Kristensen, L. S., Hansen, T. B., Venø, M. T., & Kjems, J. (2018) · Oncogene · doi:10.1038/onc.2017.361 · Cited by 1,326
Han, D., Li, J., Wang, H., Su, X., Hou, J., Gu, Y., Qian, C., Lin, Y., Liu, X., Huang, M., et al. (2017) · Hepatology · doi:10.1002/hep.29270 · Cited by 1,214
Self-citationIntra-tumor heterogeneity from a cancer stem cell perspective
Prasetyanti, P. R., & Medema, J. P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0600-4 · Cited by 800
Zhang, M., Zhao, K., Xu, X., Yang, Y., Yan, S., Wei, P., Liu, H., Xu, J., Xiao, F., Zhou, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06862-2 · Cited by 740
Mateescu, B., Kowal, E. J. K., van Balkom, B. W. M., Bartel, S., Bhattacharyya, S. N., Buzás, E. I., Buck, A. H., de Candia, P., Chow, F. W. N., Das, S., et al. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1286095 · Cited by 720
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Self-citationExosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis
Zhang, H., Deng, T., Liu, R., Bai, M., Zhou, L., Wang, X., Li, S., Wang, X., Yang, H., Li, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15016 · Cited by 562
Self-citationTechnical challenges of working with extracellular vesicles
Ramirez, M. I., Amorim, M. G., Gadelha, C., Milic, I., Welsh, J. A., Freitas, V. M., Nawaz, M., Akbar, N., Couch, Y., Makin, L., et al. (2018) · Nanoscale · doi:10.1039/c7nr08360b · Cited by 516
CircRNAs and cancer: Biomarkers and master regulators
Arnaiz, E., Sole, C., Manterola, L., Iparraguirre, L., Otaegui, D., & Lawrie, C. H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.12.002 · Cited by 415
CSCD: a database for cancer-specific circular RNAs
Xia, S., Feng, J., Chen, K., Ma, Y., Gong, J., Cai, F., Jin, Y., Gao, Y., Xia, L., Chang, H., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx863 · Cited by 397
Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer Cells
Zhou, Y., Tozzi, F., Chen, J., Fan, F., Xia, L., Wang, J., Gao, G., Zhang, A., Xia, X., Brasher, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1674 · Cited by 374
Schell, J. C., Olson, K. A., Jiang, L., Hawkins, A. J., Van Vranken, J. G., Xie, J., Egnatchik, R. A., Earl, E. G., DeBerardinis, R. J., & Rutter, J. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.026 · Cited by 363 · cited 13×
“The current study is designed to research the mechanism of drug resistance in colorectal cancer (CRC).”
BackgroundInfluentialPKM2 contributes to cancer metabolism
Wong, N., Ojo, D., Yan, J., & Tang, D. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.01.031 · Cited by 348
A modular platform for targeted RNAi therapeutics
Kedmi, R., Veiga, N., Ramishetti, S., Goldsmith, M., Rosenblum, D., Dammes, N., Hazan-Halevy, I., Nahary, L., Leviatan-Ben-Arye, S., Harlev, M., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-017-0043-5 · Cited by 320
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer
Chaneton, B., & Gottlieb, E. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.04.003 · Cited by 294
Wang, X., Zhang, H., Bai, M., Ning, T., Ge, S., Deng, T., Liu, R., Zhang, L., Ying, G., & Ba, Y. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.001 · Cited by 192
Self-citationChemoresistance in Cancer Cells: Exosomes As Potential Regulators of Therapeutic Tumor Heterogeneity
Sharma, A. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0184 · Cited by 85
Verma, D. D., Levchenko, T. S., Bernstein, E. A., & Torchilin, V. P. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.08.029 · Cited by 59
Cited by
The emerging roles of circRNAs in cancer and oncology
Kristensen, L. S., Jakobsen, T., Hager, H., & Kjems, J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00585-y · Cited by 1,256
Targeting circular RNAs as a therapeutic approach: current strategies and challenges
He, A. T., Liu, J., Li, F., & Yang, B. B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00569-5 · Cited by 549
Yang, E., Wang, X., Gong, Z., Yu, M., Wu, H., & Zhang, D. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00359-5 · Cited by 494
Self-citationRoles and mechanisms of exosomal non-coding RNAs in human health and diseases
Li, C., Ni, Y.-Q., Xu, H., Xiang, Q.-Y., Zhao, Y., Zhan, J.-K., He, J.-Y., Li, S., & Liu, Y.-S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00779-x · Cited by 406
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
Self-citation
Metadata
- Authors
- Wang, X., Zhang, H., Yang, H., Bai, M., Ning, T., Deng, T., Liu, R., Fan, Q., Zhu, K., Li, J., Zhan, Y., Ying, G., & Ba, Y.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2020-01-24
- Volume
- 14
- Issue
- 3
- Pages
- 539-555
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2998701262
- Cited by
- 490
- References
- 27
- FWCI
- 23.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.